Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2010 Sep 27.
Published in final edited form as: Proteomics. 2009 Mar;9(5):1274–1292. doi: 10.1002/pmic.200800354

Preliminary Quantitative Profile of Differential Expression between Rat L6 Myoblasts and Myotubes by Stable Isotope Labeling by Amino acids in Cell Culture

Ziyou Cui 1,2,3,*, Xiulan Chen 1,2,*, Bingwen Lu 4, Sung Kyu Park 4, Tao Xu 4, Zhensheng Xie 1, Peng Xue 1, Junjie Hou 1,2, Haiying Hang 5, John R Yates III 4, Fuquan Yang 1
PMCID: PMC2946197  NIHMSID: NIHMS148354  PMID: 19253283

Abstract

Defining the mechanisms governing myogenesis has advanced in recent years. Skeletal-muscle differentiation is a multi-step process controlled spatially and temporally by various factors at the transcription level. To explore those factors involved in myogenesis, stable isotope labeling with amino acids in cell culture (SILAC), coupled with high accuracy mass spectrometry (LTQ-Orbitrap), was applied successfully. Rat L6 cell line is an excellent model system for studying muslce myogenesis in vitro. When mononucleate L6 myoblast cells reach confluent in culture plate, they could transform into multinucleate myotubes by serum starvation. By comparing protein expression of L6 myoblasts and terminally differentiated multinucleated myotubes, 1170 proteins were quantified and 379 proteins changed significantly in fully differentiated myotubes in contrast to myoblasts. These differentially expressed proteins are mainly involved in inter-or intracellular signaling, protein synthesis and degradation, protein folding, cell adhesion and extracelluar matrix, cell structure and motility, metabolism, substance transportation, etc. These findings were supported by many previous studies on myogenic differentiation, of which many up-regulated proteins were found to be involved in promoting skeletal muscle differentiation for the first time in our study. In sum, our results provide new clues for understanding the mechanism of myogenesis.

Keywords: Quantitative proteomics, SILAC, Skeletal-muscle differentiation, 2D-LC-LTQ-Orbitrap

1 Introduction

Skeletal-muscle differentiation is a complicated process coordinated by several transcription factors [1, 2]. Under the control of those transcription factors, proliferating myoblasts withdraw from the cell cycle, and then elongate, adhere, and fuse into multinucleated myotubes. Finally, matured myotubes convert into myofibres, which are capable of muscle contraction. A number of muscle differentiation factors have been discovered such as the myogenic regulatory factors (MRFs) and the myocyte enhancer binding-factors (MEFs). The expression of these transcription factors, such as MyoD, Myogenin, Myf5 and Mef2, are controlled positively by the P38/MAPK, Wnt and Sonic hedgehog (Shh) pathways, and are inhibited by BMPs and the Notch/Delta pathway in muscle precursors [1, 3]. When the positive regulation factors are dominant, the transcriptions of muscle-specific genes are activated and the differentiation process is initiated. Although the main factors orchestrating skeletal-muscle differentiation are well defined, little is known about how these growth factors and signal pathways act on myogenic differentiation synergistically [13]. When myoblasts proliferate to skeletal cells, many characteristics, from the morphological to the conformational, will change significantly. It is reasonable to speculate that many additional cellular components are involved in myogenesis. Accumulating evidences suggest that myogenesis was regulated spatio-temporally by many cellular components; therefore, identifying additional components underlying networks that promote skeletal-muscle differentiation could lead to new insights into the process of myogenesis.

Quantitative proteomics allows measurement of differential protein expression [4, 5]. Tannu et al examined total cellular proteins, membrane-, and nuclear-enriched proteins using 2-D gel electrophoresis between proliferating mouse myoblasts of C2C12 cells and fully differentiated myotubes. [6]. The proteins they identified are mainly involved in cell signaling, cell cycle and cell shape in differentiating C2C12 cells. Gonnet and colleagues identified 105 proteins with expressional variance in differentiating human myoblasts of different myogenic period by 2D DAGE. They found that some unique proteins may participate in human muscle differentiation [7]. Kislinger et al used a gel-free shotgun proteomics method together with label-free quantitative proteomics to profile expression changes in crude nuclei during differentiation stages [8]. Hierarchical clustering of the resulting protein profiles and gene expression found that several types of proteins may be involved in myogenic process, such as integrin, septin. On the whole, these studies have presented more information in principle about the characterization of skeletal muscle differentiation by proteomics methods, but hard work on myogenesis still need to be done because of the very complex myogenic process. Moreover, there are many divergences amongst the previous studies based on molecular methods or proteomics methods. To further discover additional information about the differentiation process, we sought to use stable isotope labeling methods together with shotgun proteomics to quantitate protein expression. Stable isotope labeling with amino acids in cell culture (SILAC) has been combined with highly sensitive tandem mass spectrometry to create a simple, straightforward, and efficient approach for large-scale protein quantification [5,9,10]. SILAC relies on metabolic incorporation of a “light” or “heavy” isotopic form of the amino acid into cellular proteins [9]. SILAC have been applied in various biological fields to detect the biological changes of protein abundance, protein modifications states, and protein-protein interactions [10]. Ong and colleagues used the myogenic differentiation of C2C12 cells as a model to establish and confirm the SILAC method, but they didn’t present the myogenesis-related proteins in details [9]. In this study, we employed SILAC method with 2D-LC and LTQ-Orbitrap Hybrid Mass Spectrometer to determine protein expression differences between rat L6 myoblasts and myotubes for the first time.

2 Materials and Methods

Materials

Analytical grade chemicals were obtained from Sigma (St. Louis, USA). Milli-Q water was used unless otherwise mentioned. Normal high glucose DMEM media, fetal bovine serum (FBS), glutamine, sodium pyruvate, PBS, penicillin and streptomycin were purchased from Invitrogen (Carlsbad, CA, USA). DMEM media deficient in arginine was purchased from JRH Biosciences (Lenexa, KA, USA). Dialyzed FBS was purchased from Biological Industries (Kibbutz Beit Haemek, Israel). Both Light 12C6 14N4 L- arginine and heavy 13C6 15N4 L-arginine were obtained from Spectra Stable Isotopes (Columbia, KS, USA). Protease inhibitor cocktail tablets were obtained from Roche (Basel, Switzerland). Sequence grade trypsin was purchased from Promega (Madison, WI, USA). HPLC grade acetonitrile, methanol, and formic acid were obtained from J. T. Baker (Phillipsburg, PA, USA). Primary antibodies to tubulin-β, MyoD, desmin, 14-3-3γ, Prohibitin-2, and HRP-conjugated secondary antibodies were purchased from Abcam (Cambridge, UK). HRP-conjugated Primary antibody to GADPH was purchased from Kangcheng (Shanghai, China). SuperSignal® west Femto trial kit was obtained from Pierce (Rockford, IS, USA).

Cell culture and isotopic metabolic labelling

Rat L6 myoblasts were maintained in DMEM with 4mM L-glutamine, 4.5g/L glucose, 50 UI/ml Penicillin and 50 ug/ml streptomycin, additionally supplemented with 10% (v/v) FBS (growth medium,GM). Once myoblasts reached confluence, differentiation was induced by lowering the serum concentration to 2% (differentiation medium, DM). For western blot, L6 myoblasts in common media were subcultured into six 100mm of culture plates. After differentiation was induced, media were changed every 48hrs. At day 0, day1, day2, day3, day4, and day8, one plate of cells was washed by cold PBS separately and kept at −80 °C for protein extraction later. For isotopic metabolic labeling, newly subcultured L6 cells were transfered into DMEM supplemented with 8% dialyzed FBS plus 2% normal FBS and light 12C6 14N4 L-arginine or heavy 13C6 15N4 L-arginine instead of common GM. L6 myoblasts in light media were induced into myotubes. L6 myoblasts were subcultured in heavy 13C6 15N4 L-arginine for at least seven population doublings. Light myotubes and heavy myoblasts were washed three times with ice-cold PBS separately for protein extraction.

Protein extraction

The process of protein extraction for either MS analysis or western blot is same. The following steps were carried out at 4 °C. Cells were scraped into 8M urea with protease inhibitor cocktail tablet (Roche, Basel, Switzerland) and sonicated for cells lysis separately. After centrifugation for 30 min at 20,000g in a bench-top centrifuge (Thermo Fisher Scientific, Waltham, MA, USA), the supernatants were collected and kept at −80°C for analysis. Protein concentrations were measured using the Bradford method.

In-solution digestion

Extracted protein samples from heavy myoblasts and light myotubes were combined at a 1:1 ratio.In-solution digestion was performed with the following protocol. Briefly, 100ug of protein mixture was dissolved in 8M urea and 25mM NH4HCO3, reduced with 10mM DTT for 1 hour, alkylated by 40mM iodacetamide in the dark for 45 minutes at room temperature, and then 40mM DTT was added to quench the iodacetamide for 30 min at room temperature. After diluting 8M urea with 25mM NH4HCO3 to 1.6 M, sequence grade trypsin was added at a ratio of 1:30 and digested at 37 °C for overnight. Tryptic digestion was stopped by adding formic acid to a 1% final concentration.

2D-LC-MS/MS analysis

Digests were centrifuged at 16000g for 10 min prior to analysis. The supernatant was analyzed by two dimensional liquid chromatography (2D-LC) on an LTQ Orbitrap XL (Thermo Fisher Scientific, Waltham, USA) following the method below [11]. For single analyses, 100 µg of peptide mixtures were pressure-loaded onto a two-dimensional silica capillary column packed with 3cm of C18 resin (Synergi 4u Hydro-RP 80A, Phenomenex, CA, USA) and 3cm of strong cation exchange resin (Luna 5u SCX 100A, Phenomenex, USA) . The buffer solutions used were 5% acetonitrile/0.1% formic acid (buffer A), 80% acetonitrile/0.1% formic acid (buffer B), and 500 mM ammonium acetate/5% acetonitrile/0.1% formic acid (buffer C). The two-dimensional column was first desalted with buffer A and then eluted using an eight-step salt gradient ranging from 0 to 500 mM ammonium acetate. The effluent of the two-phase column in each case was directed onto a 10cm of C18 analytical column (100 µm i.d.) with a 3–5 µm spray tip. Step 1 consisted of a 100-min gradient from 0%–100% buffer B. Steps 2–9 had the following profile: 3 min of 100% buffer A, 3 min of X% buffer C, a 10-min gradient from 0%–15% buffer B, and a 97-min gradient from 15%–55% buffer B. The 3-min buffer C percentages (X) were 5%, 10%, 15%, 20%, 30%, 40%, 55%, and 75% respectively, for the 8-step analysis. The final step, the gradient contained: 3 min of 100% buffer A, 20 min of 100% buffer C, a 10-min gradient from 0%–15% buffer B, and a 107-min gradient from 15%–70% buffer B. Nano-electrospray ionization was accomplished with a spray voltage of 2.5 kV and a heated capillary temperature of 230°C. A cycle of one full-scan mass spectrum (400–2000 m/z) followed by six data-dependent tandem mass spectra was repeated continuously throughout each step of the multidimensional separation. All tandem mass spectra were collected using normalized collision energy (a setting of 35%), an isolation window of 3 m/z, and 1 micro-scan. Application of mass spectrometer scan functions and HPLC solvent gradients were controlled by the XCalibur data system (Thermo Fisher, Waltham, USA).

Data analysis and bioinformatics

MS and tandem mass spectra were extracted from the XCalibur data system format (.RAW) into MS1 and MS2 formats (Mc-Donald et al. 2004) by RAW_Xtractor [12]. The target database was the EBI-IPI rat database; the target database was attached with common contaminants such as keratins; the whole database (target + contaminants) was then reversed and attached. Tandem mass spectra were interpreted by SEQUEST using an EBI-IPI rat database (Version 3.17, 2006). Sequences for common contaminants such as keratins, IgGs, protease autolysis products are added to the database and then a copy is reversed and appended. Results were filtered, sorted, and displayed using the DTASelect2 program [13]. Only peptides with ≥ 95% confidence score, maximum Sp rank of 1000 and a ΔCn score of ≥ 0.1 were considered. In addition, a minimum sequence length of seven amino acid residues was required. The false positive rate for protein identification was kept below 1%. Quantitative ratios were determined by the software CenSus version 0.9 [14]. The annotations of proteins were obtained from SwissProt and TrEMBL protein database. For proteins without descriptions, annotations was done by searching the IPI, SwissProt and TrEMBL protein database with BlastP for homologous proteins with descriptions. The PANTHER classification system was used for protein sorting (www.pantherdb.org) with slight modification where a few protein groups with similar annotation were combined. The STRING (http://string.embl.de/), a proteins and their interactions prediction system, was used to retrieve protein associations.

Western blotting

L6 cells were washed three times with cold PBS and protein was extracted as described above. Equivalent amounts of protein (10µg per lane) were separated by SDS-PAGE and electroblotted onto 0.45-um HybondTM-P PVDF membranes (GE healthcare, Piscataway, NJ, USA) by the semi-dry method. Binding of nonspecific proteins to membranes was blocked by incubating these in blocking buffer consisting of 5% non-fat milk in TBS plus 0.05% Tween 20 (TBST) for 1 h at 25°C. Membranes were then incubated at 4°C overnight with primary antibodies diluted in blocking buffer. Membranes were washed three times with TBST, incubated with HRP-conjugated secondary antibodies for 1 h, and then washed three times again with TBST. Finally, immunoreactive proteins on the membranes were detected by SuperSignal® west Femto trial kit and exposed to x-ray film. Western blots were scanned and gray scales were quantified by ImageQuant TL (GE healthcare, Piscataway, NJ, USA). L6 cells cultured for western blotting were harvested three times. Western blotting for every selected protein was repeated three times for every batch of total protein extract.

3 Result and discussion

3.1. Morphological conversion of L6 Cells

Rat L6 cell is an excellent model system for developmental biology associated with cell proliferation, signal transduction and cell fate determination. Normally, L6 myoblast cells were cultured in DMEM media supplemented with 10% fetal bovine serum. In our experiments, with fetal bovine serum decreasing from 10% to 2% in DMEM media, mononucleate L6 myoblast in good conditions fused and transformed into multinucleate myotubes very quickly. One day latter after serum deprivation, myocytes are scattered in the cell culture plate. In spite of that, the shapes of L6 cells were distinct from myoblasts. After 2 days, about 35% area of culture plate was occupied by myocytes. After 3 days more than 85% of cells have fused into elongated myotubes. At the end of day 4, giant elongated multinucleate myotubes have outspread apparently everywhere on the culture plate. As Fig. 1 shows, the morphology of cells from myoblasts to myotubes has changed significantly (Figure 1). Accompanied with the morphological conversion of myoblast into myotubes, some muscle-specific proteins were expressed in high level in myotubes in comparison with myoblasts. We examined muscle-differentiation marker desmin and MyoD by western blot (Figure 2a). As the figure 2a shows that the expressional levels of these proteins were increased gradually during myogenic process but decreased in D8 myotubes. In addtion, our SILAC results show that some other muscle-differentiation markers, such as myosin heavy chain (MHC), skeletal muscle actin alpha, and myosin heavy polypeptide 2, also were up-regulated during myogenic process. In conclusion, L6 myoblasts had well differentiated into myotubes.

Figure 1.

Figure 1

The light micrographs of cultured L6 cells were enlarged by 10*10. D0 represents that the myoblasts before differentiation initiation were grown in DMEM supplemented with 10% FBS. D1, D2, D3 and D4 indicates that L6 cells have been cultured in DMEM with 2% FBS for one, two, three and four days, respectively. D4 were fully differentiated myotubes. D8 indicates myotubes have been serum-starved for another four days starting from D4.

Figure 2.

Figure 2

Western blotting. (A) Western blotting of L6 differentiation marker or differentiation associated prtoteins in L6 blasts to L6 myotubes. (B) Validation of SILAC ratio by western blotting.

3.2. Protein identification and quantification

The morphological conversion of L6 cells from myoblasts to myotubes is presumed to be driven by proteins that follow tissue- and cell specific expression. The goal of this work was to find expression differences between rat L6 myoblasts and myotubes. The tryptic peptides were analyzed by 2D-LC-LTQ-Orbitrap MS system [11]. For protein identification, a decoy database was used and the false positive rate for protein identification was kept below 1% in this study. After filtering with stringent parameters, 12,729 peptides and 2,767 proteins were identified from all experiments (see supplementary table 1). Among these proteins, 1170 proteins were quantified with high confidence (see supplementary table 1 and 2). 780 proteins (about 67%) were quantified with two or more peptides (see supplementary figure 1). Among the quantified proteins, 342 proteins were up-regulated (≥1.5-fold changes, see Table1) and 37 proteins were down-regulated (≤0.5-fold changes) in fully differentiated myotubes (see Table 2). The left proteins were considered as no significant changes (see supplementary table 1). Our results show that the expression of many conserved proteins, such as tubulin beta chain, tubulin beta 2, tubulin β 5, and actin β (actin, cytoplasmic 1), remains stable, which suggests the accuracy of the quantitative results in our experiment to some extent. To further validate the accuracy of the quantitative results by different methods, several proteins with different SILAC quantitative ratio were quantified again by western blotting. Figure 3 shows the results of western blotting for tubulin-β, 14-3-3γ, prohibitin-2 and GADPH are strongly consistent with the quantitative results determined by mass spectrometry.

Table 1.

Classification of Proteins with the Ratio ≥1.5

Description IPI ID Average Ratio
Average±SD
Quantification
Peptide Num
UniProtKB
ID/AC
Gene ID
Mediators of Signaling Pathway
Dual specificity mitogen-activated protein kinase 1
(MAPKK 1)
IPI00231247.8 1.75±NA 1 Q01986 170851
Guanine nucleotide-binding protein G(i), alpha-2
subunit
IPI00231925.7 1.79 ±0.01 3 P04897 81664
Hypothetical protein LOC361120 IPI00364617.2 1.53±NA 1 Q4QQT7 361120
Inositol 1,4,5-trisphosphate receptor type 3(IP3R-3) IPI00206986.1 1.55±NA 1 Q63269 25679
latent transforming growth factor beta binding
protein 1
IPI00389331.1 1.80±0.00 2 Q00918 59107
Membrane associated progesterone receptor
component 2
IPI00373197.1 2.15±0.15 2 Q5XIU9 361940
Phosphatidylethanolamine-binding protein IPI00230937.4 1.62±NA 1 P31044 29542
PREDICTED: A kinase (PRKA) anchor protein 2 IPI00364858.3 4.05±NA 1 Q5U301 298024
PREDICTED: similar to Dual specificity protein
phosphatase 3
IPI00568511.1 1.95±NA 1 498003
PREDICTED: similar to mitogen-activated protein
kinase 4 isoform (Map4k4)
IPI00357885.3 2.28±NA 1 301363
PREDICTED: similar to Ran-binding protein 10 IPI00365184.2 1.87±NA 1 361396
PREDICTED: similar to receptor expression
enhancing protein 5
IPI00360246.2 3.34 ±0.22 2 364838
PREDICTED: similar to Semaphorin 3C IPI00372650.3 1.88±NA 1 296787
Prenylated Rab acceptor protein 1 IPI00208565.1 2.18±NA 1 O35394 83583
Prohibitin-2 IPI00190557.2 1.94 ±0.18 4 Q5XIH7 114766
RAB10, member RAS oncogene family IPI00555185.1 2.18±0.02 3 Q5RKJ9 50993
Ras-related protein Rab-2A IPI00202570.1 1.50±NA 1 P05712 65158
Reticulocalbin 3, EF-hand calcium binding domain IPI00207050.5 55.97±NA 1 Q63399 494125
SH2-containing inositol phosphatase 2 IPI00205291.1 3.02±1.10 2 Q9WVR3 65038
Signal sequence receptor, alpha IPI00561555.1 1.78±NA 1 Q4V7D1 361233
Splice Isoform 3 of Protein kinase C and casein
kinase substrate in neurons 2 protein
IPI00231216.1 1.55±NA 1 Q9QY17 124461
Striatin, calmodulin binding protein 3 IPI00476338.2 2.37±0.19 4 P58405 114520
Translocon-associated protein gamma subunit IPI00196589.2 1.67±NA 1 Q08013 81784
A-kinase anchor protein 11 IPI00210194.1 1.84±NA 1 Q62924 498549
Protein Synthesis
3-hydroxyisobutyrate dehydrogenase, mitochondrial
precursor
IPI00202658.1 2.05±NA 1 P29266 63938
60S ribosomal protein L5 IPI00230914.4 3.83 ±3.73 5 P09895 81763
Asparaginyl-tRNA synthetase IPI00421313.1 1.99 ±0.27 7 Q6TUD1 291556
Cc2-5 IPI00382192.1 4.16±NA 1 Q7TP13 307759
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase 63 kDa subunit precursor
IPI00188059.2 1.65 ±0.05 3 P25235 64701
Elongation factor 1-alpha 1 IPI00195372.1 1.58 ±0.04 13 P62630 171361
Elongation factor 2 IPI00203214.5 1.61 ±0.10 18 P05197 29565
ERGIC-53 protein precursor IPI00210116.2 1.54 ±0.06 3 116666
Eukaryotic translation elongation factor 1 delta IPI00471525.2 2.07 ±0.07 8 Q68FR9 300033
Eukaryotic translation initiation factor 2 subunit 1 IPI00230830.4 1.73±NA 1 P68101 54318
Eukaryotic translation initiation factor 3 subunit 9 IPI00363771.3 1.50 ±0.06 6 Q4G061 288516
Eukaryotic translation initiation factor 4A2 IPI00193595.3 2.07 ±0.96 7 Q52KC1(m) 303831
GERp95 IPI00214529.3 1.91±NA 1 Q9QZ81 59117
Glutamyl-prolyl-tRNA synthetase IPI00421357.2 1.98 ±0.32 3 Q6TXE9 289352
Hypothetical protein LOC619440 IPI00201819.1 1.64 ±0.05 2 Q5XI97 619440
IKIP1 protein IPI00199778.1 1.62±0.05 3 Q5EAJ6 314730
Leucine rich repeat containing 47 (predicted) IPI00359172.1 2.00 ±0.00 2 362672
Leucyl-tRNA synthetase IPI00363236.2 1.57±NA 1 Q5PPJ6 291624
Phenylalanine-tRNA synthetase-like, beta subunit IPI00202379.1 1.71 ±0.31 3 Q68FT7 301544
PREDICTED: eukaryotic translation elongation
factor 1 gamma
IPI00470317.3 3.04 ±0.03 2 Q68FR6 293725
PREDICTED: similar to Eif3s1 protein IPI00364189.1 1.50 ±0.10 2 A0JPM9 311371
PREDICTED: similar to Eukaryotic translation
elongation factor 1 beta 2
IPI00476899.1 2.45±NA 1 363241
PREDICTED: similar to eukaryotic translation
initiation factor 3, subunit 10 theta, 150/170kDa
IPI00372810.2 1.59 ±0.11 2 Q4G020 292148
PREDICTED: similar to Glycyl-tRNA synthetase IPI00364262.2 1.90 ±0.06 3 Q5I0G4 297113
PREDICTED: similar to isoleucine-tRNA synthetase IPI00365783.3 2.04±NA 1 Q6NXK4(m) 306804
PREDICTED: similar to Methionine-tRNA
synthetase
IPI00366397.2 1.71±0.00 2 299851
PREDICTED: similar to Mitochondrial 28S
ribosomal protein S30
IPI00214903.3 1.66±NA 1 Q9D0G0(m) 294767
PREDICTED: similar to Signal recognition particle
68
IPI00368134.2 1.63 ±0.24 2 363707
PREDICTED: similar to Tryptophanyl-tRNA
synthetase
IPI00365914.2 2.40 ±0.02 3 Q6P7B0 314442
PREDICTED: similar to Tu translation elongation
factor, mitochondrial
IPI00371236.2 1.56 ±0.00 2 293481
Probable ATP-dependent RNA helicase DDX46 IPI00208266.2 1.59±NA 1 Q62780 245957
Prolyl 4-hydroxylase alpha-1 subunit precursor IPI00209863.2 1.97 ±0.26 2 P54001 64475
Prolyl 4-hydroxylase alpha-2 subunit precursor IPI00372370.2 1.77±0.00 2 360526
Ribophorin I IPI00204365.2 1.63 ±0.10 5 Q6P7A7 25596
Seryl-aminoacyl-tRNA synthetase 1 IPI00373410.3 2.40 ±0.09 4 Q6P799 266975
syntaxin 12 IPI00208759.2 1.74±NA 1 O88385 65033
Threonyl-tRNA synthetase, cytoplasmic IPI00559880.1 1.98±0.04 3 Q5XHY5 294810
Transcriptional activator protein Pur-beta IPI00189358.2 3.76 ±0.80 3 Q68A21 498407
Transitional endoplasmic reticulum ATPase IPI00212014.2 1.50±0.13 13 P46462 116643
Tyrosyl-tRNA synthetase IPI00366785.2 1.66±NA 1 Q4KM49 313047
WD repeat domain 77 IPI00368916.1 1.59±NA 1 Q4QR85 310769
Proteolysis
26S protease regulatory subunit 4 IPI00211733.1 1.88±NA 1 P62193 117263
26S protease regulatory subunit 7 IPI00421600.7 1.78 ±0.10 4 Q63347 25581
ATPase family AAA domain-containing protein 1 IPI00566676.1 1.55±NA 1 309532
Dipeptidyl-peptidase 2 precursor IPI00230946.4 3.14±NA 1 Q9EPB1 83799
Fxna IPI00390597.2 1.73±NA 1 Q6UPR8 373544
Insulin-like growth factor binding protein 5 protease IPI00199325.1 4.11 ±0.24 4 Q9QZK5 65164
Lon IPI00205076.1 2.19 ±0.01 3 Q924S5 170916
Midline-1 IPI00231578.4 2.65±NA 1 P82458 54252
Mitochondrial-processing peptidase beta subunit,
mitochondrial precursor
IPI00209980.5 2.35±NA 1 Q03346 64198
PREDICTED: aminopeptidase puromycin sensitive IPI00372700.1 2.22 ±0.15 5 Q8VID2 50558
PREDICTED: proteasome (prosome, macropain)
subunit, beta type 5
IPI00230992.4 2.50±NA 1 Q91X53 29425
PREDICTED: similar to 26S proteasome
non-ATPase regulatory subunit 11
IPI00370382.1 1.52 ±0.03 3 Q8BG32 303353
PREDICTED: similar to 26S proteasome subunit
p40.5
IPI00202283.1 1.58 ±0.49 2 Q9WVJ2 365388
PREDICTED: similar to Expressed sequence
AI314180
IPI00367234.2 1.76 ±0.08 3 313196
PREDICTED: similar to HECT domain containing 1 IPI00365611.2 1.97±NA 1 362736
PREDICTED: similar to Psmc6 protein IPI00362105.1 1.82±NA 1 Q32PW9 289990
Prenylcysteine oxidase precursor IPI00198080.1 1.54±NA 1 Q99ML5 246302
Proteasome (Prosome, macropain) 26S subunit,
ATPase 3
IPI00190392.3 1.52±NA 1 Q63569 29677
Proteasome (Prosome, macropain) 26S subunit,
non-ATPase, 2 (PSMD2)
IPI00370456.1 1.58 ±0.19 10 Q4FZT9 287984
Proteasome 26S subunit, non-ATPase, 3 IPI00370009.1 1.56 ±0.05 5 Q5U2S7 287670
Proteasome subunit alpha type 1(PSMA1) IPI00191748.3 1.72±NA 1 P18420 29668
Proteasome subunit alpha type 2 IPI00231757.11 1.77 ±0.07 3 P17220 29669
Proteasome subunit alpha type 3 IPI00476178.2 4.42±0.01 2 Q6IE67 408248
Proteasome subunit alpha type 4 IPI00231046.8 1.61 ±0.00 2 P21670 29671
Proteasome subunit alpha type 5 IPI00191502.5 1.50±0.03 5 P34064 29672
Proteasome subunit beta type 1 (PSMB1) IPI00191749.5 1.64 ±0.28 3 P18421 94198
Proteasome subunit beta type 2 IPI00188584.1 1.61 ±0.02 3 P40307 29675
Proteasome subunit beta type 4 precursor IPI00191505.3 1.60±NA 1 P34067 58854
Proteasome, 26S, non-ATPase regulatory subunit 6 IPI00189463.1 1.70 ±0.05 4 Q6PCT9 289924
Protective protein for beta-galactosidase IPI00464785.1 1.91 ±0.00 2 Q6AYS3 296370
Prothrombin precursor (Fragment) IPI00189981.1 5.18±NA 1 P18292 29251
Secernin 1 IPI00202627.1 1.83±NA 1 Q6AY84 502776
Tripeptidyl-peptidase 2 IPI00213579.2 1.59±NA 1 Q64560 81815
Ubiquitin-conjugating enzyme E2 variant 2 IPI00339040.2 1.67 ±0.12 2 Q7M767 287927
Molecular Chaperone
10 kDa heat shock protein, mitochondrial IPI00326433.10 2.20 ±0.04 3 P26772 25462
60 kDa heat shock protein, mitochondrial precursor IPI00339148.2 1.53 ±0.04 8 P63039 63868
78 kDa glucose-regulated protein precursor IPI00206624.1 1.75 ±0.06 13 P06761 25617
Calnexin Precursor IPI00199636.1 1.76±0.23 8 P35565 29144
Chaperonin subunit 6a IPI00188111.1 1.50±0.06 6 Q3MHS9 288620
Heat shock 70 kDa protein 4/Ischemia responsive 94
kDa protein
IPI00387868.2 1.83±0.12 3 O88600 266759
Heat shock cognate 71 kDa protein IPI00208205.1 1.58 ±0.07 8 P63018 24468
Heat shock protein (HSP) 90-beta IPI00471584.5 1.50 ±0.09 9 P34058 301252
Heat-shock protein beta-1 IPI00201586.1 2.55 ±0.24 4 P42930 24471
Heat-shock protein beta-8 IPI00189624.1 2.09±NA 1 Q9EPX0 113906
Hsc70-interacting protein IPI00199273.1 1.83 ±0.05 3 P50503 81800
Hypoxia up-regulated 1 IPI00559738.1 1.94±NA 1 Q63617 192235
Kelch repeat and BTB domain-containing protein 10 IPI00190417.1 9.96±NA 1 Q9ER30 117537
Pincher IPI00200271.1 3.01±NA 1 Q8R3Z7 192204
PREDICTED: low density lipoprotein
receptor-related protein associated protein 1
IPI00364124.1 1.56±NA 1 Q99068 116565
PREDICTED: similar to CCT eta, eta subunit of the
chaperonin containing TCP-1
IPI00364286.2 1.70 ±0.21 2 297406
T-complex protein 1 subunit alpha IPI00200847.1 1.51±0.03 3 P28480 24818
Ubiquitin fusion degradation 1-like isoform 1 IPI00195248.4 1.63±NA 1 Q9ES53 84478
Cell-adhesion Proteins
Glypican-1 precursor IPI00194930.5 1.70 ±0.12 10 P35053 58920
Integrin beta-1 precursor IPI00191681.1 2.30±NA 1 P49134 24511
Lactadherin precursor IPI00188896.1 2.32 ±0.17 8 P70490 25277
Neural cell adhesion molecule 1, 140 kDa isoform
precursor
IPI00476991.1 3.88±NA 1 P13596/Q3T1H3 24586
PREDICTED: laminin, alpha 5 IPI00190577.4 2.27±NA 1 P70636 140433
PREDICTED: laminin, gamma 1 IPI00363849.2 2.70±NA 1 P97552 117036
PREDICTED: nidogen 2 IPI00372786.3 2.43 ±0.33 9 Q5M812 302248
PREDICTED: similar to alpha 3 type VI collagen
isoform 1 precursor
IPI00360737.2 1.51 ±0.10 4 367313
PREDICTED: similar to Elastin microfibril
interfacer 1
IPI00199867.1 2.83 ±0.25 7 298845
PREDICTED: similar to laminin B1 IPI00365542.2 1.50 ±0.05 2 298941
PREDICTED: similar to Transmembrane 4
superfamily member 6
IPI00201753.1 3.18 ±0.00 2 Q5RJZ3 302313
PREDICTED: similar to type XV collagen IPI00364868.2 3.21 ±0.45 4 Q4G024 298069
PREDICTED: similar to Vinculin IPI00365286.3 1.55 ±0.12 17 Q9ESQ3 305679
Procollagen C-endopeptidase enhancer 1 precursor IPI00194566.1 2.44 ±0.06 4 O08628 29569
Protein-lysine 6-oxidase precursor IPI00214661.1 2.56±NA 1 P16636 24914
Splice Isoform 1 of Fibronectin precursor IPI00200757.1 2.30 ±0.17 50 P04937 25661
OX-2 membrane glycoprotein precursor(Cd200) IPI00193967.2 5.26±NA 1 P04218 24560
PREDICTED: similar to Fibulin-1 precursor IPI00370411.2 1.92±NA 1 315191
PREDICTED: similar to fibulin-2 IPI00388257.3 1.55±0.90 8 Q8CJG7 282583
Cell Structure and Motility
Actin, alpha cardiac IPI00194087.3 1.61±0.13 10 P68035 29275
Actin, alpha skeletal muscle IPI00189813.1 1.98 ±1.38 11 P68136 29437
Actin-related protein 2/3 complex subunit 1A IPI00200845.1 2.19±NA 1 Q6PCU9 81824
Microtubule-associated protein 1S IPI00362631.1 1.81±NA 1 290640
Double cortin and calcium/calmodulin-dependent
protein kinase-like 1
IPI00373202.2 11.43±NA 1 O08875 83825
General vesicular transport factor p115 IPI00324618.3 1.57 ±0.20 2 P41542 56042
Hypothetical protein RGD1305887 IPI00195673.1 2.09 ±1.41 15 Q4QQV0 307351
Isoform 1 of Tropomyosin alpha-3 chain(Tpm3) IPI00372259.4 1.58±0.65 5 Q63610 117557
Kinesin-1 heavy chain IPI00364904.2 4.43 ±0.52 10 Q2PQA9 117550
Microtubule-associated protein 1A IPI00199693.2 1.76±NA 1 P34926 25152
Microtubule-associated protein 4 IPI00393975.2 1.71 ±0.09 4 Q5M7W5 367171
Microtubule-associated protein RP/EB family
member 3
IPI00360288.1 3.35±NA 1 Q5XIT1 298848
Myosin heavy chain, fast skeletal muscle, embryonic IPI00201578.1 219.81 ±2.46 4 P1284 24583
Myosin light polypeptide 4 IPI00214457.1 127.46±35.09 5 P17209 688228
Myosin, heavy polypeptide 2, skeletal muscle, adult IPI00554308.2 443.05±NA 1 Q0GC40 691644
Nestin IPI00194103.1 7.23 ±0.84 8 P21263 25491
PREDICTED: similar to cofilin IPI00369419.2 4.49±NA 1 P45592 366624
PREDICTED: similar to cytoskeleton-associated
protein 4
IPI00365982.1 1.66 ±0.17 6 362859
PREDICTED: similar to gamma-filamin IPI00358175.2 4.90 ±0.28 8 Q8VHX6(m) 362332
PREDICTED: similar to microfilament and actin
filament cross-linker protein isoform a
IPI00359003.3 3.07 ±0.48 2 362587
PREDICTED: similar to nebulin IPI00372072.2 3.43±NA 1 311029
PREDICTED: similar to titin isoform N2-B IPI00564395.1 7.65±NA 1 P97850 84015
Septin-7 IPI00204899.1 1.52 ±0.14 4 A2VCW8 64551
Smooth muscle alpha-actin IPI00197129.1 2.69±3.13 14 Q63030 81633
Spectrin alpha chain, brain IPI00209258.4 1.57 ±0.09 18 Q6IRK8 64159
Splice Isoform 1 of Tropomyosin 1 alpha chain IPI00197888.2 2.06 ±0.10 3 P04692 24851
Splice Isoform 2 of Tropomyosin beta chain IPI00187731.4 2.75 ±0.55 3 P58775 500450
Stomatin (Epb7.2)-like 2 IPI00203528.1 1.80±NA 1 Q4FZT0 298203
Transgelin IPI00231196.4 4.90 ±0.00 2 O08564 25123
Vesicle-associated membrane protein-associated
protein A
IPI00209290.2 2.25 ±0.02 5 Q9Z270 58857
Metabolism
2,4-dienoyl-CoA reductase, mitochondrial precursor IPI00213659.3 1.94 ±0.19 3 Q64591 117543
6-phosphofructokinase, muscle type IPI00231293.6 1.57±NA 1 P47858 65152
Aldose reductase IPI00231737.4 1.65 ±0.04 3 P07943 24192
Alpha-enolase IPI00464815.10 1.60 ±0.05 11 P04764 24333
Alpha-N-acetylglucosaminidase IPI00370034.2 2.01±NA 1 Q5XIA5 287711
Annexin A11 IPI00364621.2 1.76±NA 1 Q5XI77 290527
Asparagine synthetase IPI00471908.5 4.10±NA 1 P49088 25612
Aspartate aminotransferase, cytoplasmic IPI00421513.6 1.63±NA 1 P13221 24401
ATP synthase alpha chain, mitochondrial precursor IPI00396910.1 1.93 ±0.29 5 P15999 65262
ATP synthase B chain, mitochondrial precursor IPI00196107.1 2.23±0.00 2 P19511 171375
ATP synthase beta chain, mitochondrial precursor IPI00551812.1 2.08 ±0.13 22 P10719 171374
ATP synthase delta chain, mitochondrial precursor IPI00198620.1 2.04±0.05 2 P35434 245965
ATP synthase D chain, mitochondrial IPI00230838.4 2.48 ±0.00 2 P31399 641434
ATP synthase, H+ transporting, mitochondrial F1
Complex, gamma polypeptide 1
IPI00396906.1 2.21±NA 1 Q6PCU0 116550
Beta-hexosaminidase alpha chain precursor IPI00394353.1 1.74±0.09 3 Q641X3 300757
Beta-hexosaminidase beta chain precursor IPI00464518.1 1.55±NA 1 Q6AXR4 294673
Biliverdin reductase A precursor IPI00230874.10 7.20±NA 1 P46844 116599
Citrate synthase IPI00206977.1 2.10±0.33 2 Q8VHF5 170587
COX15 homolog, cytochrome c oxidase assembly
protein
IPI00361315.2 1.74±NA 1 Q3T1G9 309391
Cytochrome c oxidase polypeptide Va,
mitochondrial precursor
IPI00192246.1 2.48 ±0.03 3 P11240 252934
Cytochrome c, somatic IPI00231864.4 1.90±0.03 3 P62898 25309
D-3-phosphoglycerate dehydrogenase IPI00475835.2 1.60 ±0.00 2 O08651 58835
Dihydrolipoamide dehydrogenase IPI00365545.1 2.64 ±0.16 2 Q6P6R2 298942
Dihydrolipoamide S-acetyltransferase IPI00231714.3 1.67 ±0.66 4 P08461 81654
Electron transfer flavoprotein beta-subunit IPI00364321.2 1.91±NA 1 Q68FU3 292845
Fructose-bisphosphate aldolase A IPI00231734.4 3.16 ±0.10 13 P05065 24189
Fumarate hydratase, mitochondrial precursor IPI00231611.7 1.91 ±0.85 4 P14408 24368
Glucose phosphate isomerase IPI00364311.1 2.09±0.10 4 Q6P6V0 292804
Glucosidase, alpha acid IPI00400579.1 1.61 ±0.65 5 Q6P7A9 367562
Glyceraldehyde-3-phosphate dehydrogenase IPI00212647.2 2.76 ±0.19 10 P04797 24383
GTP:AMP phosphotransferase mitochondrial IPI00362243.6 2.38 ±0.06 2 P29411 26956
Hsd17b4 protein IPI00326948.2 1.66 ±0.00 2 Q6IN39 79244
Hypothetical LOC361596 IPI00464897.1 1.53 ±0.17 4 Q6DGF1 361596
Hypothetical protein LOC360975 IPI00215093.1 1.66 ±0.08 4 Q5XI78 360975
Isocitrate dehydrogenase [NAD] subunit beta,
mitochondrial precursor
IPI00357924.1 1.51 ±0.25 4 Q68FX0 94173
Lactoylglutathione lyase IPI00188304.2 1.53±0.01 3 Q6P7Q4 294320
L-lactate dehydrogenase A chain IPI00197711.1 2.10±0.11 6 P04642 24533
Low molecular mass ubiquinone-binding protein IPI00382312.3 2.36±NA 1 Q7TQ16 497902
LRRGT00113 IPI00196629.3 2.00±NA 1 499358
Malate dehydrogenase, mitochondrial IPI00566583.1 2.04±0.09 8 81829
Methylmalonate-semialdehyde dehydrogenase
[acylating], mitochondrial precursor
IPI00205018.2 4.11±NA 1 Q02253 81708
Mitochondrial-processing peptidase alpha subunit,
mitochondrial
IPI00195551.1 2.06 ±0.05 3 P20069 296588
N-acylglucosamine 2-epimerase IPI00204162.1 2.17±0.00 2 P51607 81759
NADH-cytochrome b5 reductase IPI00231662.5 1.50 ±0.07 8 P20070 25035
Nicotinamide nucleotide transhydrogenase IPI00555265.1 1.90±0.26 2 Q5BJZ3 310378
Nucleoside diphosphate kinase A IPI00194404.5 1.54 ±0.05 7 Q05982 191575
Peptidase D IPI00364304.2 1.78±NA 1 Q5I0D7 292808
PREDICTED: dihydrolipoamide branched chain
transacylase E2
IPI00373418.3 1.96±0.00 2 Q99PU6 29611
PREDICTED: similar to
catechol-O-methyltransferase domain containing 1
IPI00365293.2 1.98±NA 1 305685
PREDICTED: similar to Cox7a2l protein IPI00365505.2 2.49±NA 1 P28075 316064
PREDICTED: similar to Cytochrome c oxidase
polypeptide VIb
IPI00389152.3 1.68 ±0.11 4 502592
PREDICTED: similar to
glyceraldehyde-3-phosphate dehydrogenase
IPI00554039.1 2.78 ±0.21 10 498099
PREDICTED: similar to Phosphoacetylglucosamine
mutase
IPI00205603.3 2.80 ±0.06 2 363109
PREDICTED: similar to pyrroline-5-carboxylate
synthetase short isoform
IPI00372524.3 1.52 ±0.32 9 361755
PRx III (Thioredoxin-dependent peroxide reductase,
mitochondrial)
IPI00208215.1 2.01 ±0.07 3 Q9Z0V6 64371
Pyruvate dehydrogenase E1 component alpha
subunit, somatic form, mitochondrial precursor
IPI00191707.3 4.27 ±4.91 3 P26284 29554
Pyruvate dehydrogenase E1 component subunit beta,
mitochondrial precursor
IPI00194324.1 2.91 ±1.75 3 P49432 289950
Serum deprivation response protein IPI00362416.1 3.41±NA 1 Q66H98 316384
Superoxide dismutase [Mn], mitochondrial precursor IPI00211593.1 1.57 ±0.00 2 P07895 24787
Trifunctional enzyme alpha subunit, mitochondrial
precursor
IPI00212622.1 1.71 ±0.08 10 Q64428 170670
Trifunctional enzyme beta subunit, mitochondrial
precursor
IPI00198467.1 1.66±NA 1 Q60587 171155
Triosephosphate isomerase IPI00231767.4 3.72 ±0.91 2 P48500 24849
Ubiquinol-cytochrome c reductase core protein I IPI00471577.1 2.52 ±0.36 4 Q68FY0 301011
Ubiquinol-cytochrome c reductase core protein II IPI00480805.1 2.78±0.54 4 P32551 293448
PREDICTED: similar to cytochrome c-1 IPI00366416.1 2.60 ±0.56 4 300047
SIALIDASE-1 PRECURSOR. IPI00201456.5 2.07±NA 1 Q99PW3 24591
Fumarylacetoacetate hydrolase domain-containing
protein 1
IPI00368708.2 2.54±NA 1 Q6AYQ8 302980
Long-chain-fatty-acid--CoA ligase 1 IPI00188989.1 4.29 ±1.17 3 P18163 25288
Phosphoglycerate kinase 1 IPI00231426.5 2.17 ±0.16 7 P16617 24644
PREDICTED: similar to inosine monophosphate
dehydrogenase 1 isoform b
IPI00480747.2 1.72±NA 1 362329
PREDICTED: similar to NADH dehydrogenase
(ubiquinone) 1 alpha subcomplex, assembly factor 1
IPI00373108.2 2.44±NA 1 296086
Pyruvate dehydrogenase [lipoamide] kinase isozyme
1, mitochondrial precursor
IPI00204957.1 4.57±NA 1 Q63065 116551
Sulfated glycoprotein 1 precursor IPI00195160.1 1.72 ±0.32 2 P10960 25524
Acyl-Coenzyme A thioesterase 2, mitochondrial IPI00358498.2 1.64 ±0.00 2 O55171 302640
PREDICTED: similar to Myotubularin-related
protein 2
IPI00362271.3 1.61±NA 1 315422
PREDICTED: similar to phosphoenolpyruvate
carboxykinase 2
IPI00388232.3 1.77 ±0.43 2 361042
Serine hydroxymethyl transferase 2 IPI00195109.3 1.80 ±0.08 2 Q5U3Z7 299857
Splice Isoform 1 of Lipid phosphate
phosphohydrolase 1
IPI00193763.1 4.59±NA 1 O08564 64369
Long-chain-fatty-acid--CoA ligase 3 IPI00205908.1 3.25 ±0.70 3 Q63151 114024
NAD(P)H:quinone oxidoreductase type 3,
polypeptide A2
IPI00371971.2 2.29±0.28 2 Q5EB81 304805
PREDICTED: similar to Pyruvate dehydrogenase
kinase, isoenzyme 3
IPI00192133.3 1.98±NA 1 296849
Adenylate kinase isoenzyme 4, mitochondrial IPI00204311.1 6.46±NA 1 Q9WUS0 29223
NADH dehydrogenase subunit 4 IPI00200487.1 1.55±NA 1 P05508
acyl-CoA thioesterase 7 IPI00213571.1 1.84±NA 1 Q64559 26759
Dehydrogenase/reductase (SDR family) member 7B IPI00369545.2 3.09±NA 1 Q5RJY4 287380
11 kDa protein IPI00390086.2 1.83±NA 1 Q6IBB3(h) 690441
Ubiquinol-cytochrome c reductase complex 11 kDa
protein, mitochondrial precursor
IPI00369093.1 2.48±NA 1 Q5M9I5 366448
20alpha-hydroxysteroid dehydrogenase IPI00189189.2 23.55±NA 1 Q91XV8 171516
NADH dehydrogenase (Ubiquinone) Fe-S protein 1 IPI00358033.1 1.67±NA 1 Q66HF1 301458
87 kDa protein IPI00212665.2 1.76 ±0.12 2 116645
Similar to CG6105-PA IPI00421711.1 2.58±NA 1 Q6PDU7 300677
Hypothetical protein LOC314432 IPI00368347.2 1.63 ±0.04 8 Q5U300 314432
Transporter or Channel
ADP/ATP translocase 2 IPI00200466.2 1.78 ±0.28 3 Q09073 25176
ATPase, H+ transporting, V1 subunit E isoform 1 IPI00400615.1 1.63 ±1.16 2 Q6PCU2 297566
Cationic amino acid transporter-1 IPI00190498.1 1.81±NA 1 Q8VIA9 25648
Fragile X mental retardation gene 1, autosomal
homolog
IPI00373184.2 3.19 ±0.34 3 Q5XI81 361927
Mitochondrial 2-oxoglutarate/malate carrier protein IPI00231261.6 1.97±NA 1 P97700 64201
Na-K-Cl cotransporter IPI00212590.1 2.34±NA 1 Q9QX10 83629
Nuclear protein localization protein 4 homolog IPI00191492.2 1.51±NA 1 Q9ES54 140639
PREDICTED: secretory carrier membrane protein 3 IPI00206037.5 1.52±NA 1 Q9ERM8 65169
PREDICTED: similar to ATPase, H+ transporting,
V1 subunit A, isoform 1
IPI00373076.1 1.86 ±0.41 2 360716
PREDICTED: similar to importin 7 IPI00206234.2 1.89 ±0.62 3 308939
PREDICTED: similar to p59 immunophilin IPI00358443.2 1.59±NA 1 Q8K3U8 260321
PREDICTED: similar to Tweety homolog 2 IPI00361325.2 3.49±NA 1 287803
Rho/rac guanine nucleotide exchange factor IPI00368617.2 1.66 ±0.05 3 Q5FVC2 310635
Sideroflexin-1 IPI00213735.2 9.59±NA 1 Q63965 364678
Similar to SEC24 related gene family, member IPI00365299.2 1.55 ±0.21 3 685144
Slc25a3 protein IPI00209115.2 2.51 ±0.03 5 Q6IRH6 245959
Sodium- and chloride-dependent taurine transporter IPI00327953.2 2.67±0.07 2 P31643 29464
Splice Isoform SERCA2B of
Sarcoplasmic/endoplasmic reticulum calcium
ATPase 2
IPI00190020.3 2.20 ±0.00 2 Q71UZ2 29693
Splice Splice Isoform IIBA of Dynamin-2 IPI00210319.2 1.59±NA 1 P39052 25751
Vacuolar ATP synthase subunit B, brain isoform IPI00199305.1 1.96 ±0.11 5 P62815 117596
Vacuolar ATP synthase subunit F IPI00198291.1 1.67±NA 1 P50408 116664
PREDICTED: similar to peroxisomal integral
membrane protein
IPI00366455.1 1.86±NA 1 300083
Cell Cycle,Cell Proliferation and Differentiation
Casein kinase II subunit alpha IPI00192586.1 1.69±NA 1 P19139 116549
NG,NG-dimethylarginine dimethylaminohydrolase 1 IPI00231194.4 1.81±NA 1 O08557 64157
Nucleosome assembly protein 1-like 4 IPI00366110.3 1.53 ±0.05 2 361684
PREDICTED: similar to cullin 4A IPI00364684.2 1.61±NA 1 361181
PREDICTED: similar to hepatic multiple inositol
polyphosphate phosphatase
IPI00364031.1 2.69 ±0.00 2 499084
Single-stranded DNA-binding protein, mitochondrial
precursor
IPI00196750.1 1.82 ±0.20 2 P28042 54304
Others and Molecular Function Unclassified
37 kDa protein IPI00562745.1 2.94±NA 1
9 kDa protein IPI00567137.1 2.28 ±0.77 2
Coiled-coil domain-containing protein 47 precursor IPI00203647.1 1.92 ±0.00 2 Q5U2X6 303606
Cold shock domain-containing protein E1 IPI00190971.1 1.62±0.00 2 P18395 117180
Complement component 1, Q subcomponent-binding
protein, mitochondrial precursor
IPI00361686.4 2.26 ±0.15 4 O35796 29681
Cysteine-rich with EGF-like domain protein 1
precursor
IPI00202520.1 2.87±NA 1 Q4V7F2 312638
FK506-binding protein 9 precursor IPI00215190.1 1.57 ±0.00 2 Q66H94 297123
Hypothetical protein IPI00389960.2 1.87±NA 1 Q5XI01 686883
Hypothetical protein LOC498174 IPI00394488.2 1.84±NA 1 Q5RK08 498174
Hypothetical protein RGD1306649 IPI00197896.1 2.46 ±0.20 2 Q4FZT8 288772
Kidney predominant protein NCU-G1 IPI00196226.1 1.55 ±0.00 2 Q68FV6 295231
LOC500199 protein IPI00204675.4 1.60±NA 1 Q4KM70 500199
Major vault protein IPI00231381.7 1.92 ±0.03 2 Q62667 64681
Myeloid-associated differentiation marker IPI00339007.1 2.17±NA 1 Q6VBQ5 369016
N-acylsphingosine amidohydrolase 1 IPI00421601.3 1.81 ±0.02 2 Q9EQJ6 84431
Nicalin precursor IPI00369465.2 2.15±NA 1 Q5XIA1 314648
Nucleolar protein 3 IPI00209297.1 2.35 ±0.08 2 Q62881 85383
O-GlcNAcase IPI00208152.1 17.41±NA 1 Q8VIJ5 154968
Paraspeckle protein 1 IPI00203753.1 1.52±NA 1 Q4KLH4 305910
Peroxisomal biogenesis factor 11b IPI00210003.1 2.31±NA 1 Q4KM24 310682
Pleckstrin homology domain containing, family C IPI00362106.2 1.99 ±0.14 3 Q5XI19 289992
Poliovirus receptor IPI00326594.11 8.10±NA 1 25066
PREDICTED: ATPase, H+ transporting, lysosomal
accessory protein 2
IPI00358308.2 2.24±NA 1 Q6AXS4 302526
PREDICTED: similar to 0910001A06Rik protein IPI00366405.2 1.87 ±0.00 2 299909
PREDICTED: similar to ARL6IP2 IPI00365499.3 2.17±NA 1 Q562A0 298757
PREDICTED: similar to C21ORF80 IPI00360543.2 1.79 ±0.00 2 309686
PREDICTED: similar to
Coiled-coil-helix-coiled-coil-helix domain
containing 6
IPI00364520.2 2.04 ±0.00 2 297436
PREDICTED: similar to collagen alpha 1(IV) chain
precursor - mouse
IPI00362887.2 1.57 ±0.00 3 Q5FWY9 290905
PREDICTED: similar to GPI transamidase
component PIG-T precursor
IPI00373349.1 1.50 ±0.00 2 296360
PREDICTED: similar to heparan sulfate
proteoglycan 2
IPI00388323.4 2.33 ±0.21 24 Q62980 117511
PREDICTED: similar to Histidine triad
nucleotide-binding protein 2
IPI00358757.2 1.81±0.00 2 313491
PREDICTED: similar to mKIAA0312 protein IPI00196914.4 1.58±0.04 3 P51593 501546
PREDICTED: similar to NEDD9 interacting protein
with calponin homology and LIM domains
IPI00371967.2 2.10±NA 1 294520
PREDICTED: similar to Pre-B-cell leukemia
transcription factor interacting protein 1
IPI00201858.3 4.00 ±4.69 2 A2VD12 310644
PREDICTED: similar to RIKEN cDNA
0710008K08
IPI00210521.2 2.27±0.00 2 361185
PREDICTED: similar to RIKEN cDNA
5033414D02
IPI00209463.2 1.90±NA 1 293888
PREDICTED: similar to RIKEN cDNA 5730434I03
gene
IPI00364212.2 1.77 ±0.00 2 305284
PREDICTED: similar to signal recognition
particle,72 kDa subunit
IPI00565085.1 1.64±0.14 3 499086
PREDICTED: similar to Transcriptional activator
protein PUR-alpha
IPI00197411.1 1.62 ±0.09 4 307498
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3
precursor
IPI00331772.4 1.97 ±0.22 3 Q5U367 288583
Proliferation related acidic leucine rich protein
PAL31
IPI00192336.1 1.68±NA 1 Q9EST6 170724
Protein FAM98A IPI00554081.1 1.73±NA 1 Q5FWT1 313873
Protein KIAA0152 precursor IPI00371173.2 2.32 ±0.00 2 Q5FVQ4 304543
PTPRF interacting protein, binding protein 1 (liprin
beta 1)
IPI00567984.1 1.63±0.00 2 312855
Reticulon 3, isoform A1 IPI00421506.1 1.64 ±0.20 4 A1L1I6 140945
Secreted acidic cysteine rich glycoprotein IPI00557175.1 2.54±0.15 7 P16975 24791
Similar to PRUNEM1 IPI00368646.1 3.17±NA 1 Q6AYG3 310664
Splice Isoform 2 of
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2
precursor
IPI00208888.1 1.74 ±0.32 4 Q811A3 300901
Tangerin IPI00203791.2 4.55±NA 1 Q5PQM3 309169
Thymosin beta-10 IPI00231695.5 2.61±NA 1 P63312 50665
Transmembrane emp24 protein transport domain
containing 9
IPI00364707.1 1.91 ±0.00 2 Q5I0E7 361207
Transmembrane protein 109 precursor IPI00372499.1 2.21±NA 1 Q6AYQ4 361732
LOC360721 protein IPI00608138.1 2.87±NA 1 Q4QQV3 360721
Up-regulated during skeletal muscle growth protein
5
IPI00202111.1 2.28 ±0.00 2 Q9JJW3 171069
WD-containing protein IPI00205633.6 2.30±NA 1 Q9R037 246152

Table 2.

The List of Proteins with the Ratio ≤05

Description IPI ID Average Ratio
Average±SD
Quantification
Peptide Num
UniProtKB
ID/AC
Gene ID
Alcohol dehydrogenase class 4 mu/sigma chain IPI00324743.1 0.38 ±0.03 3 P41682 171178
Amidophosphoribosyltransferase precursor IPI00198619.1 0.43±NA 1 P35433 117544
APEX (Fragment) IPI00200918.1 0.48 ±NA 1 Q99PF3 79116
Capping protein IPI00464670.1 0.39 ±0.00 2 Q6AYC4 297339
CD14 antigen IPI00231949.5 0.24±NA 1 Q63691 60350
Galectin-3 IPI00194341.4 0.44 ±0.01 5 P08699 83781
Glutaredoxin-1 IPI00231191.6 0.49 ±0.07 2 Q9ESH6 64045
Mevalonate kinase IPI00214563.1 0.20 ±NA 1 P17256 81727
Minichromosome maintenance protein 7 IPI00371012.2 0.49±0.07 4 Q1PS21 288532
Mtap6 protein (Fragment) IPI00212447.2 0.31±NA 1 Q6AYX8 29457
N-myc downstream regulated gene 1 IPI00421389.1 0.38±NA 1 Q6JE36 299923
NORBIN IPI00205396.1 0.44±NA 1 O35095 89791
Pleckstrin homology-like domain, family B,
member 1
IPI00207827.2 0.36±NA 1 Q63312 171434
PREDICTED: cadherin 11 IPI00211883.2 0.43 ±0.02 2 Q9JIW2 84407
PREDICTED: similar to 2610304F09Rik protein IPI00358454.2 0.46 ±0.00 2 307527
PREDICTED: similar to Coronin, actin binding
protein 1C
IPI00388015.3 0.33±0.46 3 B2RYG0 501841
PREDICTED: similar to DNA replication licensing
factor MCM3
IPI00361669.2 0.44±NA 1 367976
PREDICTED: similar to DNA replication licensing
factor MCM3
IPI00371781.2 0.44±NA 1 316273
PREDICTED: similar to Filamin B IPI00373752.2 0.47 ±0.12 6 306204
PREDICTED: similar to Lmnb2 protein IPI00366190.3 0.42 ±NA 1 299625
PREDICTED: similar to Stromal cell-derived factor
2 precursor
IPI00369655.1 0.38±NA 1 287470
PREDICTED: similar to TF-1 apoptosis related
protein 19
IPI00193547.2 0.33 ±NA 1 292814
PREDICTED: similar to Tripartite motif protein 47 IPI00361534.1 0.3±NA 1 690374
PREDICTED: similar to Williams-Beuren
syndrome deletion transcript 9 homolog
IPI00370333.1 0.29±NA 1 Q2V6G6 368002
Prostaglandin F2 receptor negative regulator
precursor
IPI00208280.2 0.47 ±0.27 3 Q62786 29602
prostaglandin-endoperoxide synthase 1 IPI00567836.1 0.48±0.01 3 Q66HK3 24693
Proteasome inhibitor PI31 subunit IPI00391791.2 0.27±NA 1 Q5XIU5 682071
Reck reversion-inducing-cysteine-rich protein with
kazal motifs
IPI00358750.2 0.48 ±NA 1 313488
Ribonucleotide reductase M1 IPI00361151.2 0.47±NA 1 Q5U2Q5 365320
RNA terminal phosphate cyclase domain 1 IPI00201443.1 0.37 ±NA 1 Q68FS8 295395
RNA-binding motif protein 3 IPI00367437.3 0.50 ±0.00 2 Q925G0 114488
Small nuclear ribonucleoprotein polypeptide A IPI00364044.3 0.20 ±0.00 2 Q5U214 292729
Testis derived transcript IPI00560148.2 0.4±NA 1 Q2LAP6 500040
Transcriptional repressor CTCF IPI00207172.2 0.47±NA 1 Q9R1D1 83726
UDP-glucose 6-dehydrogenase IPI00195803.1 0.44±0 2 O70199 83472
Wiskott-Aldrich syndrome protein-interacting
protein
IPI00470232.5 0.3±NA 1 Q6IN36 117538
Xanthine dehydrogenase/oxidase IPI00231694.6 0.50 ±0.07 3 P22985 497811

Figure 3.

Figure 3

Functional annotations of the proteins with > 1.5 ratio in L6 myotubes compared to myoblasts. The pie chart shows the distribution of biological processes to all up regulated proteins in L6 myotubes compared to myoblasts in this study using panther classification system with modification.

3.3. The comparative profiling of protein expression

Many of the differentially expressed proteins observed in this study have been reported to be involved in myogenic regulation, and some were newly discovered by this study.

Proteins increased in expression (ratio ≥1.5) were sorted by the PANTHER Classification system (Figure 3 and Table 1). These proteins are mainly involved in inter-or intracellular signaling, protein synthesis and protein degradation, protein folding, cell adhesion and extracellular matrix, cell structure and motility, metabolism, substance transportation, etc. These patterns of up-regulation were consistent with the functional and structural characteristics of skeletal muscle cells. In order to explore functional modules of the proteins we quantified, protein interaction network was predicted by STRING (see supplementary Figure 2).

Mediators of signaling pathway

Myogenic differentiation is regulated by positive and negative signals from surroundings. After switching the cells from nutrient rich media to nutrient poor medium by lowering FBS content from 10% to 2%, L6 myoblasts are able to sense the physical and chemical signals of lowered FBS through specific membrane receptors [2]. Once L6 myoblasts sense these signals, a series of intracellular events will be triggered. The final result of these events is increased expression of MyoD and Myogenin. MyoD and Myogenin initiate multiple muscle differentiation-specific genes transcription for myogenic process [1, 2]. Although the role of mitogen-activated protein kinase (MAPK) signaling cascades in myogenesis is controversial, accumulating studies have shown that MAPK is activated during the differentiation of myogenic cell lines and is essential for the expression of muscle-specific genes [15, 16]. Activation of MAPK signaling cascades in myoblasts can modulate the activity of MyoD establishing dynamic modulation of the MyoD-induced programs of gene expression [3]. We observed that terminally differentiated myotubes increase the expression of some MAPK-pathway associated proteins, for example, Map4k4, MAPKK 1, etc. But, the amount of most MAPKs remains stable, because they are modified as functional executors at different stages of differentiation [17]. A kinase (PRKA) anchor protein 2, exhibiting protein kinase A binding, involved in actin filament organization, protein localization and the trans-membrane receptor protein serine/threonine kinase signaling pathway. Interestingly, prohibitin (PHB), a ubiquitously expressed and evolutionarily highly conserved protein, was found up-regulated once myoblasts initiated differentiation. This result is supported by western blot data (figure 2b) and the results from Tannu [6]. PHB has been found to be presented in the nucleus, the mitochondria and the plasma membrane. Gamble et al. reported that PHB participates in the activation of the Raf-MEK-ERK pathway [18, 19]. Sun and colleagues reported that PHB-2 can repress muscle differentiation by inhibiting MyoD and MEF2 in C2C12 cells [20]. From these clues, prohibitin may belong to MAPKs cascade and play important role in muscle differentiation. Besides MAPK related factors, we also found some other signaling molecules were up-regulated in muscle cells, such as inositol 1, 4, 5-triphosphate receptor 3 (IP3R-3), latent transforming growth factor beta binding protein 1 (LTBP-1), phosphatidylethanolamine-binding protein, SH2-containing inositol phosphatase 2 (SHIP2), and guanine nucleotide-binding protein G (i), alpha-2, etc. IP3R-3, in connection with acetylcholine signaling, adrenergic signaling, endothelin signaling, PDGF signaling, chemokine and cytokine signaling and Wnt signaling etc, is the receptor for inositol 1,4,5-trisphosphate to mediates the release of intracellular calcium. The alteration of IP3R-3 abundance in muscles may be so as to match the excitation-contraction coupling of muscle cell. LTBP-1 targets latent complexes of transforming growth factor beta to the extracellular matrix. It interacts with architectural extracellular matrix macromolecules—fibrillins that form ubiquitous extracellular microfibril suprastructures in the connective tissue space. It is unknown whether or not LTBP-1 participates in myogenic initiation and myoblast fusion [21, 22]. In addition, we identified one non-muscle differentiation-promoting protein, transcriptional activator protein Pur-beta (3.76 fold). This protein is known to regulate myeloid cell differentiation. It remains unclear how these proteins function in myogenic differentiation. In our study, many myogenesis-control factors, such as MyoD and Myogenin, were not observed, probably because these proteins were very low abundance in cells.

Protein Synthesis-and Degradation-related Proteins

Synthesis of Muscle-specific protein increases significantly during the myogensis process. Many proteins associated with proteins synthesis were found up-regulated in this study, including many amino acid-tRNA synthetases, eukaryotic translation elongation factors, eukaryotic translation initiation factors and ribosomal proteins. These types of proteins also have been reported by previous studies [69]. Protein synthesis and degradation is a finely coordinate process [23]. It is well known that the protein degradation system serves as a quality-control system for abnormal proteins to maintain cellular homeostasis [24]. And yet, as early as 1997, Gardrat hypothesized that ubiquitin-proteasome pathway was involved in muscle cell differentiation [25]. In 2005, Schwartz group discovered that both MyoD and inhibitor of DNA binding 1(Id1) are rapidly degraded by the ubiquitin-proteasome pathway during the differentiation of myoblast to myotube in mouse C2C12 myoblast cells, but the reduction of Id1 is more than MyoD markedly [26]. Rapid reduction of Id1 can release repression on MyoD, then, which will trigger muscle-specific gene transcription. This shows that ubiquitin-proteasome pathway is essential to initiation of mygenic differentiation by controlling muscle differentiation-specific gene expression [26]. Proteasomes, performing ATP-dependent proteolysis, are large protein complexes formed by many subunits. In this study, we found many proteasomal proteins, such as PSMA1, PSMA 2, PSMA 3, PSMA 4, PSMA5, PSMB1, PSMB2, PSMD2, PSMD3, the 26S protease regulatory subunit 7 and 26S protease regulatory subunit 4, were up-regulated during myogenic process. From the STRING network view, it can be seen directly that these proteins have the strong interactions (supplemented figure 2). Obviously, the changes of proteolytic system we found support the theory of myogenesis addressed by preceding publications [25, 26].

Molecular Chaperone

Molecular chaperones are a group of proteins whose roles are to assist newly translated proteins to fold properly as functional mature proteins or lead the misfolded proteins to degradation mentioned above. In differentiating muscle cells, the single nascent myosin molecule must go through folding and assemble into motor thick filament with associated proteins. It has been reported that Hsp90 and Hsc70 forms a complex with newly synthesized myosin and these chaperones promote myofibril assembly [27]. In this study, Hsp90, Hsc70 (heat shock cognate 71 kDa protein), Hsc70-interacting protein, have been up-regulated by 1.50, 1.58 and 1.83 fold respectively in L6 myotube cells. In addition, glucose-regulated protein precursor, hypoxia up-regulated 1 and heat shock 70 kDa protein 4, belonging to Hsp70 family chaperone, were also up-regulated in our study. That Hsp70 were increased during differentiation of myotubes has been proved by western blot [28]. T-complex protein 1 subunit alpha (TCP-1-alpha, CCT-alpha), a molecular chaperone of actin and tubulin, has also been found to be up-regulated by 1.7 fold. CCT activity is required for cell cycle progression and cytoskeleton organization in mammalian cells [29]. In this study, we also identified some small heat shock proteins, such as HspB1 (Hsp27), HspB8 (Hsp22), and aB-crystallin. These proteins can confer resistance to apoptosis during myogenic differentiation [30]. In addition, Hsp27 controlled by P38/MAPK pathway can modify actin polymerization. These behaviors of such proteins are beneficial to myogenic differentiation. Hsp27 and Hsp22 were up-regulated 2.55 and 2.09 fold respectively. Alpha B-crystallin also has important effect on myotubes development. This protein was identified in our experiment with no quantified SILAC ratio here. But, with manually check the MS spectra intensities and integral area of peptides of αB-crystallin, we found that αB-crystallin was up-regulated during myogenic process (Data not shown). In sum, the observed up-regulated molecular chaperones of cytoskeleton proteins play the important role in the muscle differentiation.

Cell-adhesion Proteins

Myoblasts-myotubes conversion requires cell-cell mutual interaction and fusion between myoblalsts. No doubt, adhesion molecules must be involved in this process. Some cell adhesion molecules have been reported to be involved in controlling the fusion of myoblasts during muscle development [31, 32]. Grossi and colleague have shown that mechanical stimulation can promote C2C12 cells differentiation through the laminin receptor [33]. In this study many extracellular matrix linker proteins were identified and showed increased expression in the L6 terminal differentiation stage, such as integrin beta-1 precursor (2.3 fold), isoform 1 of fibronectin precursor (2.3 fold), splice isoform 2 of fibronectin precursor (2.3 fold), procollagen C-proteinase enhancer protein (2.44 fold), protein-lysine 6-oxidase precursor (2.56 fold), splice isoform short of collagen alpha-1(XII) chain (1.73 fold) and vinculin (1.55 fold).. These proteins are involved in cell adhesion, cell communication, cell motility, and maintenance of cell shape. Integrin beta-1 is a subunit of several integrin proteins. Integrin is a receptor for fibronectin, collagen, and laminins. Brzoska has shown that integrin α3 subunit participates in myoblast adhesion and fusion in vitro [34]. When α3β1 integrin binds to its ligands, intracellular signaling will be triggered, and then elicits cytoskeleton reorganization to keep cell adhesion, cell motility and cell shape. Intergin also drives Raf/MEK/ERK pathway [35], therefore, myoblast cell to cell adhesion maybe is one trigger for the transcription of muscle-specific gene. It is reasonable that enhanced expression of these proteins in terminally differentiated myocytes strengthened cell-cell, cell-matrix adhesion and provided physical stabilization and tenacity against the tensile forces generated during muscle contraction.

Cell Structure and Motility Associated Proteins

Skeletal myogenic differentiation involved in extensive changes in cell morphology and subcellular architectures. During the differentiation process, myoblasts fuse to form multinucleated myotubes. This morphological change reflects a massive structural reorganization of cytoplasmic components including subcellular organelles [36]. Two dynamic filament systems, microtubules and microfilaments, have been considered to participate actively in generating the spatial organization of the cell [37]. Realignment of nascent α-actin and myosin into sarcomeres of myofibrils depended on microtubules network reorganization [37]. Responding to this cell-shape change, many cytoskeleton proteins are up-regulated in L6 myotubes, for instance, microtubule-associated proteins, actin related protein 2/3 complex subunit 1A (Arpc1a), transgelin, dynamin-2 and kinesin-1 etc. Microtubule-associated protein 4 is found to be required for myogensis. Antisense inhibition of muscle-specific microtubule-associated protein-4 during differentiation severely perturbed myotube formation, but had no effect on growth and cell fusion [38]. Actin-related protein 2/3 formed complex with WASP or WAVE protein to mediate the actin polymerization and the formation of branched actin networks. Transgelin, an actin cross-linking/gelling protein, is also up-regulated 4.90 fold. Dynamin-2, a microtubule-associated force-producing protein involved in producing microtubule bundles and vesicular trafficking processes [39], may be also associated with myoblasts fusion. Kinesin-1, a microtubule-dependent motor required for normal distribution of cellular components, was up-regulated by 4.4 fold, which indicates that myotube is a critical dynamic cellular component in myoblast differentiation [40]. Besides microtubules, intermediate filament is another important family of cytoskeletal proteins associated with myotubes transformation. Muscle-specific intermediate filaments (IFs) include desmin, nestin, vimentin and so on [41, 42]. These proteins are synthesized by muscle cells depends on the type of muscle and its stage of development. Desmin is presented in all muscles at all stages of development and the others appear transiently or in only certain muscles [41, 42]. In our experiment, desmin was identified but its relative expression ratio in myotubes compared to myoblast wasn’t showed by Census software. However, western blot result shows the expression of desmin was up-regulated along with myogenic process. Our SILAC data shows that nestin is highly up-regulated in Day4 L6 myotubes (7.23 fold). It is well known that nestin is a crucial component in neuron differentiation, but it is less clear how nestin functions during myogenic development.

Once myocytes form, muscle-specific contractile proteins also highly express. Skeletal muscle actin α, a basic component of thin filament, was up-regulated 2 fold. Myosins are actin-based motor proteins and the main component of thick filament. Myosin heavy chain (MHC), a myotube-specific marker, was up regulated 220 fold. Myosin heavy polypeptide 2 and myosin light polypeptide 4 also were found increased intensely in L6 myotubes comparing to myoblasts. Splice isoform 1 of tropomyosin 1 alpha and Splice Isoform 2 of tropomyosin beta increased by up to about 2 fold compared with myoblasts. Tropomyosins bind to actin filaments and in association with the troponin complex regulate muscle contraction in a calcium-dependent manner.

Taken together, all of these observations are consistent with a muscle contractility function. The up-regulation of microtubule, intermediate filament and microfilament can facilitate reframed-shape of myotubes during myogensis and maintain the structural and functional integrity of skeletal muscle.

Metabolism-related Proteins

Because skeletal muscle is force-producing contractile machinery, various metabolic events, such as ATP producing, are very active during skeletal muscle contraction. In myotubes, there is an extreme demand for ATP for muscle contraction and ATP-dependent calcium signaling. To meet this demand, skeletal muscle metabolizes large mount of glucose, fatty acids and amino acids to produce energy [43]. Consistent with which, myotubes express a large number of proteins and enhance mitochondrial function to metabolize the energy-providing products. In this study, we identified 92 proteins whose expression increased at least 1.5 fold and have been annotated to be related to energy metabolism. Among this type of proteins, 24 proteins were mapped to glucose metabolism, 19 proteins to fatty acid metabolism, 21 proteins to oxidative phosphorylation/electron transport, 13 proteins to amino acid metabolism, and 24 proteins to other metabolic functions. For example, the expression level of glyceraldehyde-3-phosphate dehydrogenase was increased by 2.76 fold, long-chain fatty acid-CoA ligase by 14.26 fold, fructose-bisphosphate aldolase A by 3.16 fold, pyruvate dehydrogenase beta by 2.91 fold, mitochondrial malate dehydrogenase by 2.04 fold, citrate synthase by 2.1 fold, all of which are consistent with Ong’s result [8]. ATP synthase B chain, ATP synthase D chain, ATP synthase beta chain and ATP synthase delta chain, the enzymes for oxidative phosphorylation, have increased significantly. GADPH, a housekeeping protein, is usually used as a control for relative protein quantification by Western blot. In this study, cells increase GADPH expression from the start of differentiation (Figure 2b), but GADPH expression was down-regulated after four days starvation (day 8) because of a decrease in glycolysis. In contrast to the Western blot results for other proteins, the decreasing expression of GADPH at day 8 suggests that GADPH may not be dominant factor in differentiation.

Transporters or Channel Proteins

Consistent with excitable and contractile characteristic of muscle, some transporter or channel proteins are highly expressed in mytubes. Skeletal muscle cells are stimulated by acetylcholine released at neuromuscular junctions by motor neurons. Ion Na+ flow into cell by Na+-K+ transporters and subsequently cells produce action potentials. Once the cells are excited, their sarcoplasmic reticulums will release through sarcoplasmic/endoplasmic reticulum calcium ATPase. Ca2+ interacts with the myofibrils and induces muscular contraction. During muscular contraction, cells consume a mass of ATP and produce substantive H+. Moreover, increase of ion Ca2+ could enhance myoblasts differentiation during the myogenic process [44]. These substrates need the help of ion transporters to pass through the cytoplasmic membranes. Ionic sodium, potassium, calcium, hydrogen transporter and cationic amino acid transporter were highly expressed in finally differentiated cell.

Among the proteins with the expression ratio of <0.5 (Table 2), some have been shown to be associated with myogenic process, such as prostaglandin F2 receptor negative regulator (PTGFRN) and prostaglandin-endoperoxide synthase 1 (COX-1). PTGFRN can inhibit the effect of PG F2 by binding to PG F2 receptor. COX-1 is a rate-control enzyme of PGs synthesis. Many studies have shown that PGs including PG F2 can promote the myogenesis by different ways [45]. If it is the case, down-regulation of PGF2 receptor negative regulator can facilitate the positive effect of PG F2 on myogenic process. But down-regulation of COX-1 looks controversial to this case. And yet, Bondesen showed recently that PG I2 can inhibit myogenesis in vitro by blocking myoblast migration and fusion [46]. So, these data indicate that there are still some controversies in myogenesis and need more detailed investigations.

4 Conclusions

In conclusion, stable isotope labeling and quantitative mass spectrometry was succeeded in analyzing skeletal-muscle differentiation. In this study, isotopic arginine was introduced in the SILAC approach, therefore, only tryptic peptides with arginine carboxyl-terminal were quantified and peptides with lysine carboxyl-terminal weren’t available for quantification. Provided that SILAC labeling with arginine and lysine would improve the accuracy of protein quantification and increase the number of peptides/proteins quantified. From our data, most of the up- or down-regulated proteins we quantified in the terminally differentiated L6 cells may provide principal or accessory support for the myogenesis process. Proteins whose expressions remained unchanged during differentiation suggest alternate mechanisms, such as modification or interactions, may be involved in muscle differentiation. For example, MAPK1 and β-catenin is the pivotal node of the signaling pathway that plays an important role in the myogenic process. Their roles are still needed further data and experiment mining. By and large, SILAC was effective in trying to elucidate the molecular mechanisms of skeletal-muscle differentiation in this study, and our data can present more clues on myogenic development. Whereas, as mentioned at the very beginning of this article, skeletal-muscle differentiation is a very complicated and dynamic process that is controlled spatio-temporally by multifarious type of factors at different transcriptional levels. The transcriptions of most proteins are dynamic, and that depends on the type of muscle, its stage of development and different species. To our viewpoint, it is essential and challenging in the future how to systematically grasp the dynamic changes of different type of proteins and their tuneful integrated functions during skeletal-muscle differentiation.

Supplementary Material

Supp Figures
Supp MS Spectra
Supp Tables 1
Supp Tables 2

Acknowledgments

The research was supported by the National Basic Research Program of China (973) (grant no. 2004CB720004) and the National Natural Science Foundation of China (grant no. 30670587). JRY is supported by NIH P41 RR011823.

Abbreviations

SILAC

stable isotope labeling with amino acids in cell culture

References

  • 1.Wagers AJ, Conboy IM. Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell. 2005;122:659–667. doi: 10.1016/j.cell.2005.08.021. [DOI] [PubMed] [Google Scholar]
  • 2.Parker MH, Seale P, Rudnicki MA. Looking back to the embryo: defining transcriptional networks in adult myogenesis. Nat. Rev. Genet. 2003;4:497–507. doi: 10.1038/nrg1109. [DOI] [PubMed] [Google Scholar]
  • 3.Lluís F, Perdiguero E, Nebreda AR, Muñoz-Cánoves P. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends. Cell. Biol. 2006;16:36–44. doi: 10.1016/j.tcb.2005.11.002. [DOI] [PubMed] [Google Scholar]
  • 4.Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422:198–207. doi: 10.1038/nature01511. [DOI] [PubMed] [Google Scholar]
  • 5.Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 2005;5:252–262. doi: 10.1038/nchembio736. [DOI] [PubMed] [Google Scholar]
  • 6.Tannu NS, Rao VK, Chaudhary RM, Giorgianni F, et al. Comparative proteomes of the proliferating C(2)C(12) myoblasts and fully differentiated myotubes reveal the complexity of the skeletal muscle differentiation program. Mol. Cell. Proteomics. 2004;3:1065–1082. doi: 10.1074/mcp.M400020-MCP200. [DOI] [PubMed] [Google Scholar]
  • 7.Gonnet F, Bouazza B, Millot GA, Ziaei S, et al. Proteome analysis of differentiating human myoblasts by dialysis-assisted two-dimensional gel electrophoresis (DAGE) Proteomics. 2008;8:264–278. doi: 10.1002/pmic.200700261. [DOI] [PubMed] [Google Scholar]
  • 8.Kislinger T, Gramolini AO, Pan Y, Rahman K, et al. Proteome dynamics during C2C12 myoblast differentiation. Mol. Cell. Proteomics. 2005;4:887–901. doi: 10.1074/mcp.M400182-MCP200. [DOI] [PubMed] [Google Scholar]
  • 9.Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics. 2002;1:376–386. doi: 10.1074/mcp.m200025-mcp200. [DOI] [PubMed] [Google Scholar]
  • 10.Mann M. Functional and quantitative proteomics using SILAC. Nat. Rev. Mol. Cell. Biol. 2006;7:952–958. doi: 10.1038/nrm2067. [DOI] [PubMed] [Google Scholar]
  • 11.Delahunty C, Yates JR., 3rd Protein identification using 2D-LC-MS/MS. Methods. 2005;35:248–255. doi: 10.1016/j.ymeth.2004.08.016. [DOI] [PubMed] [Google Scholar]
  • 12.McDonald WH, Tabb DL, Sadygov RG, MacCoss MJ, et al. MS1, MS2, and SQT-three unified, compact, and easily parsed file formats for the storage of shotgun proteomic spectra and identifications. Rapid. Commun. Mass. Spectrom. 2004;18:2162–2198. doi: 10.1002/rcm.1603. [DOI] [PubMed] [Google Scholar]
  • 13.Cociorva D, Tabb DL, Yates JR., 3rd . Validation of tandem mass spectrometry database search results using DTASelect in Chapter 13:Unit 13.4 of Curr Protoc Bioinformatics. New Jersey: John Wiley & Sons Inc; 2007. [DOI] [PubMed] [Google Scholar]
  • 14.Park SK, Venable JD, Xu T, Yates JR., 3rd A quantitative analysis software tool for mass spectrometry-based proteomics. Nat. Methods. 2008;5:319–322. doi: 10.1038/nmeth.1195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Bennett AM, Tonks NK. Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science. 1997;278:1288–1291. doi: 10.1126/science.278.5341.1288. [DOI] [PubMed] [Google Scholar]
  • 16.Keren A, Tamir Y, Bengal E. The p38 MAPK signaling pathway: a major regulator of skeletal muscle development. Mol. Cell. Endocrinol. 2006;252:224–230. doi: 10.1016/j.mce.2006.03.017. [DOI] [PubMed] [Google Scholar]
  • 17.Gredinger E, Gerber AN, Tamir Y, Tapscott SJ, Bengal E. Mitogen-activated protein kinase pathway is involved in the differentiation of muscle cells. J. Biol. Chem. 1998;273:10436–10444. doi: 10.1074/jbc.273.17.10436. [DOI] [PubMed] [Google Scholar]
  • 18.Gamble SC, Chotai D, Odontiadis M, Dart DA, et al. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene. 2007;26:1757–1768. doi: 10.1038/sj.onc.1209967. [DOI] [PubMed] [Google Scholar]
  • 19.Rajalingam K, Wunder C, Brinkmann V, Churin Y, et al. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat. Cell Biol. 2005;7:837–843. doi: 10.1038/ncb1283. [DOI] [PubMed] [Google Scholar]
  • 20.Sun L, Liu L, Yang XJ, Wu Z. Akt binds prohibitin 2 and relieves its repression of MyoD and muscle differentiation. J. Cel. Sci. 2004;117:3021–3029. doi: 10.1242/jcs.01142. [DOI] [PubMed] [Google Scholar]
  • 21.Isogai Z, Ono RN, Ushiro S, Keene DR, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J. Biol. Chem. 2003;278:2750–2757. doi: 10.1074/jbc.M209256200. [DOI] [PubMed] [Google Scholar]
  • 22.Hubmacher D, Tiedemann K, Reinhardt DP. Fibrillins: from biogenesis of microfibrils to signaling functions. Curr. Top. Dev. Biol. 2006;75:93–123. doi: 10.1016/S0070-2153(06)75004-9. [DOI] [PubMed] [Google Scholar]
  • 23.Gustavo A. Nader Molecular determinants of skeletal muscle mass: getting the “AKT” together. Int. J. Biochem. Cell Biol. 2005;37:1985–1996. doi: 10.1016/j.biocel.2005.02.026. [DOI] [PubMed] [Google Scholar]
  • 24.Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426:895–899. doi: 10.1038/nature02263. [DOI] [PubMed] [Google Scholar]
  • 25.Gardrat F, Montel V, Raymond J, Azanza JL. Proteasome and myogenesis. Mol. Biol. Rep. 1997;24:77–81. doi: 10.1023/a:1006877214153. [DOI] [PubMed] [Google Scholar]
  • 26.Sun L, Trausch-Azar JS, Ciechanover A, Schwartz AL. Ubiquitin-Proteasome- mediated Degradation, Intracellular Localization, and Protein Synthesis of MyoD and Id1 during Muscle Differentiation. J. Biol. Chem. 2005;280:26448–26456. doi: 10.1074/jbc.M500373200. [DOI] [PubMed] [Google Scholar]
  • 27.Srikakulam R, Winkelmann DA. Chaperone-mediated folding and assembly of myosin in striated muscle. J. Cell Sci. 2004;117:641–652. doi: 10.1242/jcs.00899. [DOI] [PubMed] [Google Scholar]
  • 28.Ito H, Kamei K, Iwamoto I, Inaguma Y, Kato K. Regulation of the levels of small heat-shock proteins during differentiation of C2C12 cells. Exp. Cell. Res. 2001;266:213–221. doi: 10.1006/excr.2001.5220. [DOI] [PubMed] [Google Scholar]
  • 29.Grantham J, Brackley KI, Willison KR. Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells. Exp. Cell Res. 2006;312:2309–2324. doi: 10.1016/j.yexcr.2006.03.028. [DOI] [PubMed] [Google Scholar]
  • 30.Kamradt MC, Chen F, Sam S, Cryns VL. The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J. Biol. Chem. 2002;277:38731–38736. doi: 10.1074/jbc.M201770200. [DOI] [PubMed] [Google Scholar]
  • 31.Covault J, Sanes JR. Distribution of N-CAM in synaptic and extrasynaptic portions of developing and adult skeletal muscle. J. Cell Biol. 1986;102:716–730. doi: 10.1083/jcb.102.3.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Levi G. Cell adhesion molecules during Xenopus myogenesis. Cytotechnology. 1993;11:s91–s93. [PubMed] [Google Scholar]
  • 33.Grossi A, Yadav K, Lawson MA. Mechanical stimulation increases proliferation, differentiation and protein expression in culture: Stimulation effects are substrate dependent. J. Biomech. 2007;40:3354–3362. doi: 10.1016/j.jbiomech.2007.05.007. [DOI] [PubMed] [Google Scholar]
  • 34.Brzoska E, Bello V, Darribere T, Moraczewski J. Integrin alpha3 subunit participates in myoblast adhesion and fusion in vitro. Differentiation. 2006;74:105–118. doi: 10.1111/j.1432-0436.2005.00059.x. [DOI] [PubMed] [Google Scholar]
  • 35.Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911–1912. doi: 10.1126/science.1072682. [DOI] [PubMed] [Google Scholar]
  • 36.Squire JM. Architecture and function in the muscle sarcomere. Curr. Opin. Struct. Biol. 1997;7:247–257. doi: 10.1016/s0959-440x(97)80033-4. [DOI] [PubMed] [Google Scholar]
  • 37.Pizon V, Gerbal F, Diaz CC, Karsenti E. Microtubule-dependent transport and organization of sarcomeric myosin during skeletal muscle differentiation. EMBO J. 2005;24:3781–3792. doi: 10.1038/sj.emboj.7600842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Mangan ME, Olmsted JB. Muscle-specific variant of microtubule-associated protein 4 (MAP4) is required in myogenesis. Development. 1996;122:771–781. doi: 10.1242/dev.122.3.771. [DOI] [PubMed] [Google Scholar]
  • 39.Kessels MM, Dong J, Leibig W, Westermann P, Qualmann B. Complexes of syndapin II with dynamin II promote vesicle formation at the trans-Golgi network. J. Cell Sci. 2006;119:1504–1516. doi: 10.1242/jcs.02877. [DOI] [PubMed] [Google Scholar]
  • 40.Ginkel LM, Wordeman L. Expression and Partial characterization of kinesin related proteins in differentiating and adult skeletal muscle. Mol. Biol. Cell. 2000;11:4143–4158. doi: 10.1091/mbc.11.12.4143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Vaittinen S, Lukka R, Sahlgren C, Hurme T, et al. The expression of intermediate filament protein nestin as related to vimentin and desmin in regenerating skeletal muscle. J. Neuropathol. Exp. Neurol. 2001;60:588–597. doi: 10.1093/jnen/60.6.588. [DOI] [PubMed] [Google Scholar]
  • 42.Paulin D, Xue Z. Landes Bioscience and Springer US press. Austin: 2006. Desmin and Other Intermediate Filaments in Normal and Diseased Muscle in Intermediate Filaments in Intermediate Filaments; pp. 1–9. [Google Scholar]
  • 43.Richardson RS. Oxygen transport and utilization: an integration of the muscle systems. Adv. Physiol. Educ. 2003;27:183–191. doi: 10.1152/advan.00038.2003. [DOI] [PubMed] [Google Scholar]
  • 44.Porter GA, Makuck RF, Rivkees SA. Reduction in intracellular calcium levels inhibits myoblast differentiation. J. Biol. Chem. 2002;277:28942–28947. doi: 10.1074/jbc.M203961200. [DOI] [PubMed] [Google Scholar]
  • 45.Horsley V, Pavlath GK. Prostaglandin F2 (alpha) stimulates growth of skeletal muscle cells via an NFATC2-dependent pathway. J. Cell Biol. 2003;161:111–118. doi: 10.1083/jcb.200208085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Bondesen BA, Jones KA, Glasgow WC, Pavlath GK. Inhibition of myoblast migration by prostacyclin is associated with enhanced cell fusion. FASEB J. 2007;21:3338–3345. doi: 10.1096/fj.06-7070com. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supp Figures
Supp MS Spectra
Supp Tables 1
Supp Tables 2

RESOURCES